Morgan Stanley’s The Beachbody Company, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 BODY.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-820
Closed 8097
2022
Q1
$0 Hold
820
﹤0.01% 8223
2021
Q4
$0 Hold
820
﹤0.01% 8200
2021
Q3
$1K Hold
820
﹤0.01% 7840
2021
Q2
$2K Buy
+820
New +$2.67K ﹤0.01% 7555

Other funds holding BODY.WS

Morgan Stanley's BODY.WS Position: Q2 2022 in Review

Morgan Stanley sold out of The Beachbody Company, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 (BODY.WS) in Q2 2022, closing a stake of 820 shares.

Morgan Stanley first reported a position in BODY.WS in Q2 2021 and held it in 4 quarters. The position peaked at $2K in Q2 2021. 21 funds tracked by Wall St. Rank hold BODY.WS as of Q2 2022.

  • Morgan Stanley reported no remaining The Beachbody Company, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 position as of Q2 2022 after selling out during the quarter.
  • Morgan Stanley sold 820 The Beachbody Company, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 shares in Q2 2022.
  • Morgan Stanley first reported a position in The Beachbody Company, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 in Q2 2021 and held it in 4 quarters.
  • Morgan Stanley's The Beachbody Company, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 position peaked at $2K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held The Beachbody Company, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 as of Q2 2022.

Based on Morgan Stanley's 13F filing for Q2 2022, filed 15 Aug 2022.